Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Renal Transplantation in CAPS Patients
NCT01029587Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2009
- Primary completion
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in catastrophic antiphospholipid syndrome (CAPS), sponsored by Johns Hopkins University. Primary endpoint: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant at 6 months. Started Nov 2009; status: completed.
02
Drugs
eculizumab
03
Conditions
catastrophic antiphospholipid syndrome (CAPS)
Beyond the preview
Go deeper on NCT01029587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029587.